JAADRCT
Dose optimization of deuruxolitinib in adults with alopecia areata
A phase 2 randomized trial.
ConclusionDeuruxolitinib 8 mg BID was associated with greater improvements in scalp hair regrowth vs deuruxolitinib 16 mg QD.
King B, Kempers S, … senior author Cassella JJournal of the American Academy of Dermatology